vs

Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.

Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($395.6M vs $220.8M, roughly 1.8× UNIVERSAL TECHNICAL INSTITUTE INC). Dolby Laboratories, Inc. runs the higher net margin — 24.0% vs 5.8%, a 18.2% gap on every dollar of revenue. On growth, UNIVERSAL TECHNICAL INSTITUTE INC posted the faster year-over-year revenue change (9.6% vs 7.1%). Over the past eight quarters, Dolby Laboratories, Inc.'s revenue compounded faster (13.9% CAGR vs 9.5%).

Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.

Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.

DLB vs UTI — Head-to-Head

Bigger by revenue
DLB
DLB
1.8× larger
DLB
$395.6M
$220.8M
UTI
Growing faster (revenue YoY)
UTI
UTI
+2.6% gap
UTI
9.6%
7.1%
DLB
Higher net margin
DLB
DLB
18.2% more per $
DLB
24.0%
5.8%
UTI
Faster 2-yr revenue CAGR
DLB
DLB
Annualised
DLB
13.9%
9.5%
UTI

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
DLB
DLB
UTI
UTI
Revenue
$395.6M
$220.8M
Net Profit
$94.9M
$12.8M
Gross Margin
88.7%
Operating Margin
28.5%
7.1%
Net Margin
24.0%
5.8%
Revenue YoY
7.1%
9.6%
Net Profit YoY
3.4%
-42.1%
EPS (diluted)
$0.99
$0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DLB
DLB
UTI
UTI
Q2 26
$395.6M
Q1 26
$346.7M
Q4 25
$346.7M
$220.8M
Q3 25
$307.0M
$222.4M
Q2 25
$315.5M
$204.3M
Q1 25
$369.6M
$207.4M
Q4 24
$357.0M
$201.4M
Q3 24
$304.8M
$196.4M
Net Profit
DLB
DLB
UTI
UTI
Q2 26
$94.9M
Q1 26
$53.3M
Q4 25
$53.3M
$12.8M
Q3 25
$49.3M
$18.8M
Q2 25
$46.1M
$10.7M
Q1 25
$91.8M
$11.4M
Q4 24
$67.8M
$22.2M
Q3 24
$58.6M
$18.8M
Gross Margin
DLB
DLB
UTI
UTI
Q2 26
88.7%
Q1 26
87.5%
Q4 25
87.5%
Q3 25
87.1%
Q2 25
86.1%
Q1 25
90.3%
Q4 24
88.6%
Q3 24
88.8%
Operating Margin
DLB
DLB
UTI
UTI
Q2 26
28.5%
Q1 26
17.9%
Q4 25
17.9%
7.1%
Q3 25
9.7%
11.2%
Q2 25
15.1%
6.9%
Q1 25
29.2%
8.1%
Q4 24
22.4%
13.6%
Q3 24
15.2%
13.3%
Net Margin
DLB
DLB
UTI
UTI
Q2 26
24.0%
Q1 26
15.4%
Q4 25
15.4%
5.8%
Q3 25
16.1%
8.4%
Q2 25
14.6%
5.2%
Q1 25
24.8%
5.5%
Q4 24
19.0%
11.0%
Q3 24
19.2%
9.6%
EPS (diluted)
DLB
DLB
UTI
UTI
Q2 26
$0.99
Q1 26
$0.55
Q4 25
$0.55
$0.23
Q3 25
$0.50
$0.33
Q2 25
$0.48
$0.19
Q1 25
$0.94
$0.21
Q4 24
$0.70
$0.40
Q3 24
$0.59
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DLB
DLB
UTI
UTI
Cash + ST InvestmentsLiquidity on hand
$594.7M
$162.8M
Total DebtLower is stronger
$101.4M
Stockholders' EquityBook value
$2.6B
$335.9M
Total Assets
$3.2B
$834.0M
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DLB
DLB
UTI
UTI
Q2 26
$594.7M
Q1 26
$644.6M
Q4 25
$644.6M
$162.8M
Q3 25
$702.6M
$169.1M
Q2 25
$699.3M
$70.7M
Q1 25
$626.6M
$96.0M
Q4 24
$520.8M
$172.0M
Q3 24
$482.0M
$161.9M
Total Debt
DLB
DLB
UTI
UTI
Q2 26
Q1 26
Q4 25
$101.4M
Q3 25
$87.1M
Q2 25
$73.8M
Q1 25
$94.4M
Q4 24
$120.1M
Q3 24
$125.7M
Stockholders' Equity
DLB
DLB
UTI
UTI
Q2 26
$2.6B
Q1 26
$2.6B
Q4 25
$2.6B
$335.9M
Q3 25
$2.6B
$328.1M
Q2 25
$2.6B
$306.8M
Q1 25
$2.6B
$293.9M
Q4 24
$2.5B
$280.0M
Q3 24
$2.5B
$260.2M
Total Assets
DLB
DLB
UTI
UTI
Q2 26
$3.2B
Q1 26
$3.2B
Q4 25
$3.2B
$834.0M
Q3 25
$3.2B
$826.1M
Q2 25
$3.2B
$740.8M
Q1 25
$3.2B
$720.4M
Q4 24
$3.2B
$753.8M
Q3 24
$3.1B
$744.6M
Debt / Equity
DLB
DLB
UTI
UTI
Q2 26
Q1 26
Q4 25
0.30×
Q3 25
0.27×
Q2 25
0.24×
Q1 25
0.32×
Q4 24
0.43×
Q3 24
0.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DLB
DLB
UTI
UTI
Operating Cash FlowLast quarter
$147.3M
$3.1M
Free Cash FlowOCF − Capex
$-19.2M
FCF MarginFCF / Revenue
-8.7%
Capex IntensityCapex / Revenue
10.1%
Cash ConversionOCF / Net Profit
1.55×
0.24×
TTM Free Cash FlowTrailing 4 quarters
$16.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DLB
DLB
UTI
UTI
Q2 26
$147.3M
Q1 26
$54.8M
Q4 25
$54.8M
$3.1M
Q3 25
$472.2M
$57.1M
Q2 25
$67.7M
$18.1M
Q1 25
$174.9M
$-789.0K
Q4 24
$106.8M
$23.0M
Q3 24
$327.3M
$67.5M
Free Cash Flow
DLB
DLB
UTI
UTI
Q2 26
Q1 26
Q4 25
$50.2M
$-19.2M
Q3 25
$435.9M
$40.6M
Q2 25
$61.3M
$6.8M
Q1 25
$168.0M
$-11.7M
Q4 24
$100.0M
$19.6M
Q3 24
$297.2M
$60.0M
FCF Margin
DLB
DLB
UTI
UTI
Q2 26
Q1 26
Q4 25
14.5%
-8.7%
Q3 25
142.0%
18.3%
Q2 25
19.4%
3.4%
Q1 25
45.5%
-5.7%
Q4 24
28.0%
9.7%
Q3 24
97.5%
30.6%
Capex Intensity
DLB
DLB
UTI
UTI
Q2 26
Q1 26
Q4 25
1.3%
10.1%
Q3 25
11.8%
7.4%
Q2 25
2.0%
5.5%
Q1 25
1.9%
5.3%
Q4 24
1.9%
1.7%
Q3 24
9.8%
3.8%
Cash Conversion
DLB
DLB
UTI
UTI
Q2 26
1.55×
Q1 26
1.03×
Q4 25
1.03×
0.24×
Q3 25
9.57×
3.04×
Q2 25
1.47×
1.69×
Q1 25
1.91×
-0.07×
Q4 24
1.57×
1.04×
Q3 24
5.59×
3.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DLB
DLB

Licensing$372.2M94%
Products and services$23.4M6%

UTI
UTI

UTI$142.8M65%
Concorde$78.0M35%

Related Comparisons